Rapid reduction in S. aureus & cytotoxins in dupilumab treated atopic dermatitis subjects

Atopic dermatitis (AD) severity correlates with S. aureus (SA) colonization and barrier dysfunction. To address the importance of IL-4&-13 on these parameters, the Atopic Dermatitis Research Network designed a 6wk, RDBPC trial (Dupilumab[DPL]:placebo/2:1) with sampling (at 0, 3, 7, 14, 21, 28 & 42 days [d]) to quantify SA, barrier and severity (EASI, NRS, IGA & SCORAD). Seventy-two moderate-severe adult AD subjects were randomized. There was a >7-fold reduction in SA (qPCR) on lesional (L) skin in DPL vs placebo group (1o endpoint [28d];P<0.001).